medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2008, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2008; 6 (3)

Pityriasis rubra pilaris. A review of therapeutic options
Pityriasis-questionary

Pérez HJ, Frías AG, Hierro OS

Language: Spanish
References: 32
Page: 180-186
PDF size: 295.09 Kb.


ABSTRACT

Pityriasis rubra pilaris (PRP) includes a group of chronic disorders with circumscribed follicular keratosis with palmoplantar keratoderma. Both familial and acquired forms have been recognized. Familial form is infrequent and usually occurs in childhood and has a bimodal distribution. We present different : retinoids, methotrexate, cyclosporin, biological agents, danazol, estanazol, pimecrolimus, fumaric acidand calcipotriol.


REFERENCES

  1. Bolognia JL, Jorizzo JL, Rapini RP, Dermatology, vol I, London, Mosby, 2004, 155-158.

  2. Goldsmith LA, Baden HP, “Pityriasis rubra pilaris”, en Freedberg IM, Eisen AZ, Wolkk K, Austen KF, Goldsmith LA(eds.), Fitzpatrick’s dermatology in general medicine, vol I, 6a ed., McGraw Hill, Nueva York, 2003, 442-444.

  3. Albert MR, Mackool BT, “Pityriasis rubra pilaris”, Int J Dermatol 1999; 38: 1-11.

  4. Jerard D, “Pityriasis rubra pilaris: a clinical review”, Dermatol Nurs 2005; 17: 448-452.

  5. Sehgal VN, Srivastava G, “(Juvenile) pityriasis rubra pilaris”, Int J Dermatol 2006; 45: 438-446.

  6. Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH, “Pityriasis rubra pilaris in children”, J Am Acad Dermatol 2002; 47: 386-389.

  7. Arnold AW, Buechner SA, “Circumscribed juvenile pityriasis rubra pilaris”, J Eur Acad Dermatol Venereol 2004; 18: 705-707.

  8. Betlloch IR, Silvestre JF, Carnero L, Albares MP, Bañuls J, “Acute Juvenile pityriasis rubra pilaris: a superantigen mediated disease?”, Pediatr Dermatol 2001;18: 411-414.

  9. Caldarola G, Zampetti A, Simone C de, Massi G, Amerio P, Feliciano C, “Circumscribed pityriasis rubra pilaris type IV”, Clin Exp Dermatol 2007; 32: 471-472.

  10. González A, Velasco E, Pozo T, Villar A del, “HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy”, Br J Dermatol 1999; 140: 931-934.

  11. Cohen PR, Prystowsky JH, “Pityriasis rubra pilaris: a review of diagnosis and treatment”, J Am Acad Dermatol 1989; 20: 801-807.

  12. Griffiths WAD, “Pityriasis Rubra Pilaris”, Clin Exp Dermatol 1980; 5(1): 105-112.

  13. Dicken CH, “Treatment of classic pityriasis rubra pilaris”, J Am Acad Dermatol 1994; 31: 997-999.

  14. Desai A, Kartono F, Rosso JQ del, “Systemic retinoid therapy: a status report in optimal use and safety of long-term therapy”, Dermatol Clin 2007; 25: 185-193.

  15. Sekula-Gibbs S, Uptmore D, Otillar L, “Retinoids”, J Am Acad Dermatol 2004; 50: 405-415.

  16. Clayton BD, Jorizzo JL, Hitchcock MG et al., “Adult pityriasis rubra pilaris: a 10-year case series”, J Am Acad Dermatol 1997; 36: 959-964.

  17. Usuki K, Sekiyama M, Shimada T et al., “Three cases of pityriasis rubra pilaris successfully treated with cyclosporina A”, Dermatology 2000; 200(4): 324-327.

  18. Liao WC, Mutasim DF, “Infliximab for the treatment of adult onset pytiriasis rubra pilaris”, Arch Dermatol 2005; 141: 423-424.

  19. 19.Wetzig T, Sticherling M, “Juvenile pitiriasis rubra pilaris: successful treatment with Ciclosporina”, Br J Dermatol 2003; 149: 202-203.

  20. 20.Gómez M, Ruelas ME, Welsh O, Arcaute HD, Ocampo-Candiani J, “Clinical improvement of pitiriasis rubra pilaris with efalizumab in a pediatric patient”, J Drugs Dermatol 2007; 6: 337-339.

  21. Gregoriou S, Argyrious G, Christofidou E et al., “Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%”, J Drugs Dermatol 2007; 6: 340-342.

  22. Coras B, Vogt TH, Ulrich H, Landthaler M, Hohenleutn U, “Fu ma - ric acid esters therapy: a new treatment modality in pityriasis rubra pilaris?”, Br J Dermatol 2005; 152: 388-389.

  23. Van de Kerkhof, PCM, Steijlen PM, “Topical treatment of pitiriasis rubra pilaris with Calcipotriol”, Br J Dermatol 1994; 130: 675-678.

  24. Katzung BG, Farmacología básica y clínica, 7a ed., Manual Moderno, México, 1999, 1021-1022, 1061-1062.

  25. Seckin D, Tula E, Ergun T, “Successful use of etanercept in type I pitiriasis rubra pilaris”, Br J Dermatol 2008; 158(3): 642-644.

  26. Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Mesh - kinpour A, “Clinical improvement of pityriasis rubra pilarias with combination etanercept and acitretina therapy”, Arch Dermatol 2007; 143: 1597-1599.

  27. Dogra S, Narang T, Radotra BD, Kanwar AJ, “Pityriasis rubra pilaris in a HIV-positive patient (type 6 PRP)”, Skinmed 2008; 7: 47-50.

  28. Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J, “Combined ultraviolet A1 radiation and acitretina therapy as a treatment option for pityriasis rubra pilaris”, Br J Dermatol 2000; 142: 574-575.

  29. Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti S, “Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab”, J Eur Acad Dermatol Venereol 2008; 22: 117-118.

  30. Sharma S, Weiss GR, Paulger B, “Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma”, Dermatology 1997; 194(2): 166-167.

  31. Elder DE, Elenitsas R, Johnson BL, Murphy GF, Lever’s histopathology of the skin, Lippincott Williams & Wilkins, Filadelfia, 2005, 203-204.

  32. González-Morán A, Román C, Yuste M et al., “Pitiriasis Rubra Pilaris aguda, posinfecciosa infantil. Tratamiento con calcipotriol”, Med




2020     |     www.medigraphic.com